Literature DB >> 11685466

The human MIP-1beta chemokine is encoded by two paralogous genes, ACT-2 and LAG-1.

W S Modi1, J Bergeron, M Sanford.   

Abstract

Human macrophage inflammatory protein-1 beta (MIP-1beta) is an Mr 8,000 acidic protein that is upregulated upon stimulation in monocytes, T cells, and other lymphocytes. This protein belongs to the CC chemokine subfamily and directs the migration of specific subsets of leukocytes. The first molecular clone was isolated in 1988, and ever since there has been confusion regarding the exact number of genes encoding this and closely related proteins. PCR primers were designed from two genomic GenBank entries to conduct single-strand conformational polymorphism analysis, sequence analysis, and PCR-RFLP, and we conclude that previously isolated clones referred to as MIP-1beta are derived from two genes, originally called ACT-2 and LAG-1. The two proteins share a common length and are identical at 89 of 92 amino acids. The first two amino acid differences, V12M and L20P, occur in the signal peptide, while the third, G70S, is in the mature protein. Within the transcribed region, the genes differ at 25 of 662 nucleotides. A survey of the NCBI expressed sequence tag database reveals that both genes are expressed in a variety of tissues, and five clones representing LAG-1 transcripts are alternatively spliced, with the 115-bp exon 2 omitted. Database searches for putative orthologues in other species revealed that the rabbit protein is about 80% similar to the two human proteins, while those of rat and mouse are 70-75% similar. Comparative sequence analysis of the human and animal proteins indicates substantially higher rates of protein evolution in the two rodents compared to human and rabbit.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685466     DOI: 10.1007/s002510100366

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  7 in total

Review 1.  Copy number variation in chemokine superfamily: the complex scene of CCL3L-CCL4L genes in health and disease.

Authors:  R Colobran; E Pedrosa; L Carretero-Iglesia; M Juan
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

2.  Haplotype diversity in the interleukin-4 gene is not associated with HIV-1 transmission and AIDS progression.

Authors:  William S Modi; Thomas R O'Brien; David Vlahov; Susan Buchbinder; Edward Gomperts; John Phair; Stephen J O'Brien; Cheryl Winkler
Journal:  Immunogenetics       Date:  2003-04-25       Impact factor: 2.846

3.  Combinatorial content of CCL3L and CCL4L gene copy numbers influence HIV-AIDS susceptibility in Ukrainian children.

Authors:  Ludmila Shostakovich-Koretskaya; Gabriel Catano; Zoya A Chykarenko; Weijing He; German Gornalusse; Srinivas Mummidi; Racquel Sanchez; Matthew J Dolan; Seema S Ahuja; Robert A Clark; Hemant Kulkarni; Sunil K Ahuja
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

4.  Independent expression of the two paralogous CCL4 genes in monocytes and B lymphocytes.

Authors:  Jun Lu; Marek Honczarenko; Steven R Sloan
Journal:  Immunogenetics       Date:  2003-12-13       Impact factor: 2.846

5.  Chemokine expression in the early response to injury in human airway epithelial cells.

Authors:  Bingqing Xie; Bharathi Laxman; Somaye Hashemifar; Randi Stern; T Conrad Gilliam; Natalia Maltsev; Steven R White
Journal:  PLoS One       Date:  2018-03-13       Impact factor: 3.240

6.  Chemokine CCL4 Induces Vascular Endothelial Growth Factor C Expression and Lymphangiogenesis by miR-195-3p in Oral Squamous Cell Carcinoma.

Authors:  Ming-Yu Lien; Hsiao-Chi Tsai; An-Chen Chang; Ming-Hsui Tsai; Chun-Hung Hua; Shih-Wei Wang; Chih-Hsin Tang
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

7.  Chemokine C-C Motif Ligand 4 Gene Polymorphisms Associated with Susceptibility to Rheumatoid Arthritis.

Authors:  Shu-Jui Kuo; Chien-Chung Huang; Chun-Hao Tsai; Horng-Chaung Hsu; Chen-Ming Su; Chih-Hsin Tang
Journal:  Biomed Res Int       Date:  2018-05-31       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.